Lipocalin 2 is present in the EAE brain and is modulated by natalizumab

Frontiers in Cellular Neuroscience

Volumn 6, Issue AUG, 2012, Pages

  Marques, Fernanda ^a,b   Mesquita, Sandro D ^a,b   Sousa, João C ^a,b   Coppola, Giovanni ^c   Gao, Fuying ^c   Geschwind, Daniel H ^c   Columba Cabezas, Sandra ^d   Aloisi, Francesca ^d   Degn, Matilda ^e   Cerqueira, João J ^a,b,f   Sousa, Nuno ^a,b,f   Correia Neves, Margarida ^a,b   Palha, Joana A ^a,b,f  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f Clinical Academic Center   (Portugal)

Author keywords

Astrocytes; Cerebrospinal fluid; Experimental autoimmune encephalomyelitis; Lipocalin 2; Multiple sclerosis; Natalizumab

Indexed keywords

IMMUNOGLOBULIN G; NATALIZUMAB; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSCRIPTOME;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CHOROID PLEXUS; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; MULTIPLE SCLEROSIS; NEUROPHYSIOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPTIC NEURITIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY;

EID: 84875411252     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2012.00033     Document Type: Article

References (30)

1. Berard, J. L., Zarruk, J. G., Arbour, N., Prat, A., Yong, V. W., Jacques, F. H., Akira, S., and David, S. (2012). Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis. Glia 60, 1145-1159.
2. Brown, D. A., and Sawchenko, P. E. (2007). Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J. Comp. Neurol. 502, 236-260.
3. Calabrese, M., Mattisi, I., Rinaldi, F., Favaretto, A., Atzori, M., Bernardi, V., Barachino, L., Romualdi, C., Rinaldi, L., Perini, P., and Gallo, P. (2010). Magnetic resonance evidence of cerebellar cortical pathology in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 81, 401-404.
4. Columba-Cabezas, S., Griguoli, M., Rosicarelli, B., Magliozzi, R., Ria, F., Serafini, B., and Aloisi, F. (2006). Suppression of established experimental autoimmune encephalomyelitis and formation of meningeal lymphoid follicles by lymphotoxin beta receptor-Ig fusion protein. J. Neuroimmunol. 179, 76-86.
5. Comi, G., Colombo, B., and Martinelli, V. (2000). Prognosis-modifying therapy in multiple sclerosis. Neurol. Sci. 21, S893-899.
6. Devireddy, L. R., Gazin, C., Zhu, X., and Green, M. R. (2005). A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 123, 1293-1305.
7. Devireddy, L. R., Hart, D. O., Goetz, D. H., and Green, M. R. (2010). A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell 141, 1006-1017.
8. Flo, T. H., Smith, K. D., Sato, S., Rodriguez, D. J., Holmes, M. A., Strong, R. K., Akira, S., and Aderem, A. (2004). Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432, 917-921.
9. Hemmer, B., Nessler, S., Zhou, D., Kieseier, B., and Hartung, H. P. (2006). Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2, 201-211.
10. Iaffaldano, P., Lucchese, G., and Trojano, M. (2011). Treating multiple sclerosis with natalizumab. Expert Rev. Neurother. 11, 1683-1692.
11. Lee, S., Kim, J. H., Seo, J. W., Han, H. S., Lee, W. H., Mori, K., Nakao, K., Barasch, J., and Suk, K. (2011). Lipocalin-2 is a chemokine inducer in the central nervous system: role of CXCL10 in lipocalin-2-induced cell migration. J. Biol. Chem. 286, 43855-43870.
12. Lee, S., Park, J. Y., Lee, W. H., Kim, H., Park, H. C., Mori, K., and Suk, K. (2009). Lipocalin-2 is an autocrine mediator of reactive astrocytosis. J. Neurosci. 29, 234-249.
13. Marques, F., Rodrigues, A. J., Sousa, J. C., Coppola, G., Geschwind, D. H., Sousa, N., Correia-Neves, M., and Palha, J. A. (2008). Lipocalin 2 is a choroid plexus acute-phase protein. J. Cereb. Blood Flow Metab. 28, 450-455.
14. Marques, F., Sousa, J. C., Coppola, G., Falcao, A. M., Rodrigues, A. J., Geschwind, D. H., Sousa, N., Correia-Neves, M., and Palha, J. A. (2009a). Kinetic profile of the transcriptome changes induced in the choroid plexus by peripheral inflammation. J. Cereb. Blood Flow Metab. 29, 921-932.
15. Marques, F., Sousa, J. C., Coppola, G., Geschwind, D. H., Sousa, N., Palha, J. A., and Correia-Neves, M. (2009b). The choroid plexus response to a repeated peripheral inflammatory stimulus. BMC Neurosci. 10, 135.
16. Naegele, M., Tillack, K., Reinhardt, S., Schippling, S., Martin, R., and Sospedra, M. (2012). Neutrophils in multiple sclerosis are characterized by a primed phenotype. J. Neuroimmunol. 242, 60-71.
17. Pedchenko, T. V., and LeVine, S. M. (1998). Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice. J. Neuroimmunol. 84, 188-197.
18. Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'connor, P. W., Sandberg-Wollheim, M., Thompson, A. J., Weinshenker, B. G., and Wolinsky, J. S. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58, 840-846.
19. Rathore, K. I., Berard, J. L., Redensek, A., Chierzi, S., Lopez-Vales, R., Santos, M., Akira, S., and David, S. (2011). Lipocalin 2 plays an immunomodulatory role and has detrimental effects after spinal cord injury. J. Neurosci. 31, 13412-13419.
20. Reboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccelli, A., Lanzavecchia, A., Engelhardt, B., and Sallusto, F. (2009). C-C chemokine receptor 6-regulated entry of T(H)-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 10, 514-523.
21. Richardson, D. R. (2005). 24p3 and its receptor: dawn of a new iron age? Cell 123, 1175-1177.
22. Theien, B. E., Vanderlugt, C. L., Eagar, T. N., Nickerson-Nutter, C., Nazareno, R., Kuchroo, V. K., and Miller, S. D. (2001). Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 107, 995-1006.
23. The Optic Neuritis Study Group. (2008). Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch. Neurol. 65, 727-732.
24. Tintore, M., Rovira, A., Rio, J., Tur, C., Pelayo, R., Nos, C., Tellez, N., Perkal, H., Comabella, M., Sastre-Garriga, J., and Montalban, X. (2008). Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 70, 1079-1083.
25. Tumani, H., Hartung, H. P., Hemmer, B., Teunissen, C., Deisenhammer, F., Giovannoni, G., and Zettl, U. K. (2009). Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol. Dis. 35, 117-127.
26. Vercellino, M., Masera, S., Lorenzatti, M., Condello, C., Merola, A., Mattioda, A., Tribolo, A., Capello, E., Mancardi, G. L., Mutani, R., Giordana, M. T., and Cavalla, P. (2009). Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J. Neuropathol. Exp. Neurol. 68, 489-502.
27. Vercellino, M., Votta, B., Condello, C., Piacentino, C., Romagnolo, A., Merola, A., Capello, E., Mancardi, G. L., Mutani, R., Giordana, M. T., and Cavalla, P. (2008). Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: a neuropathological study. J. Neuroimmunol. 199, 133-141.
28. Wang, D., Ayers, M. M., Catmull, D. V., Hazelwood, L. J., Bernard, C. C., and Orian, J. M. (2005). Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis. Glia 51, 235-240.
29. Wu, F., Cao, W., Yang, Y., and Liu, A. (2010). Extensive infiltration of neutrophils in the acute phase of experimental autoimmune encephalomyelitis in C57BL/6 mice. Histochem. Cell Biol. 133, 313-322.
30. Zlokovic, B. V. (2008). The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201.